Lyell Immunopharma Presents First in Human Trial Design of LYL797 at ESMO 2022

Retrieved on: 2022-09-12 07:01:36

Tags for this article:

Branches of biology

Medicine

Chimeric antigen receptor T cell

Lymphoma

Adoptive cell transfer

Cancer

Induced stem cells

SOUTH SAN FRANCISCO

Lyell Immunopharma Inc.

Click the tags to see associated articles and topics

Lyell Immunopharma Presents First in Human Trial Design of LYL797 at ESMO 2022. View article details on HISWAI: https://www.globenewswire.com/news-release/2022/09/12/2513667/0/en/Lyell-Immunopharma-Presents-First-in-Human-Trial-Design-of-LYL797-at-ESMO-2022.html

Excerpt

“These reprogramming technologies are designed to overcome primary ... and epigenetic reprogramming technology platforms, Gen-R™ and Epi-R™, ...

Article found on: www.globenewswire.com

View Original Article